Drug intelligence / Profile preview

Tersigan

Development stage: Unknown
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

Ba253MDI is a metered dose inhaler formulation marketed under the brand name Tersigan. It is used as a comparator drug in clinical studies for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. The specific active ingredient and mechanism of action are not detailed in the available sources, but it is administered via aerosol inhalation to provide bronchodilation or anti-inflammatory effects typical of COPD therapies[1][3]. The product has been evaluated for efficacy and safety in clinical trials involving COPD patients[1][3].

Brand names: Tersigan
Other names: Ba253MDIBa-253MDIBa 253MDITersigan aerosol

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)

Beyond the preview

Go deeper on Tersigan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tersigan.

Explore the full profile